Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 9, 3, 1, 25 and 9 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 10 molecules, respectively.
Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 9, 3, 1, 25 and 9 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 10 molecules, respectively.
Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Retinitis Pigmentosa (Retinitis) - Overview 8
Retinitis Pigmentosa (Retinitis) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 28
2-BBB Medicines BV 28
Acucela Inc 28
Allergan Plc 28
Amarantus Bioscience Holdings Inc 29
Amgen Inc 29
Applied Genetic Technologies Corp 30
Astellas Pharma Inc 30
Caladrius Biosciences Inc 31
Dompe Farmaceutici SpA 31
Eyevensys SAS 32
GenSight Biologics SA 32
Grupo Ferrer Internacional SA 33
ID Pharma Co Ltd 33
InFlectis BioScience 33
Ionis Pharmaceuticals Inc 34
Ms Science Corp 34
MimeTech Srl 35
Mimetogen Pharmaceuticals Inc 35
Nanovector srl 35
Novartis AG 36
Novelion Therapeutics Inc 36
ProQR Therapeutics NV 37
Recursion Pharmaceuticals Inc 37
ReNeuron Group Plc 38
SanBio Inc 38
Sanofi 39
Spark Therapeutics Inc 39
Sun Pharma Advanced Research Company Ltd 40
Retinitis Pigmentosa (Retinitis) - Drug Profiles 41
A-004 - Drug Profile 41
AGTC-501 - Drug Profile 43
AMRS-001 - Drug Profile 45
Antibodies to Antagonize IL-6 for Retinitis - Drug Profile 54
Antisense Oligonucleotides to Activate Usherin for Retinitis Pigmentosa - Drug Profile 55
AP-1 - Drug Profile 56
cenegermin - Drug Profile 57
CPK-850 - Drug Profile 60
cutamesine - Drug Profile 61
EYS-611 - Drug Profile 63
FAB-111 - Drug Profile 64
Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 65
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 66
Gene Therapy for Ocular Diseases - Drug Profile 67
Gene Therapy for Retinitis Pigmentosa - Drug Profile 68
Gene Therapy for Retinitis Pigmentosa - Drug Profile 69
Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile 70
Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile 71
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile 72
Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile 73
Gene Therapy to Activate RdCVF for Retinitis Pigmentosa - Drug Profile 74
Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 75
Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 76
GS-030 - Drug Profile 77
HORAPDE-6B - Drug Profile 80
HORARLBP-1 - Drug Profile 81
HORARPE-65 - Drug Profile 82
IFB-088 - Drug Profile 83
IONISRHO-2.5Rx - Drug Profile 84
KIRA-6 - Drug Profile 85
KUS-121 - Drug Profile 86
KUS-187 - Drug Profile 87
LPDF-003 - Drug Profile 88
MT-8 - Drug Profile 89
myriocin - Drug Profile 90
N-acetyl cysteine amide - Drug Profile 91
NPI-001 - Drug Profile 92
NT-501 - Drug Profile 93
OCU-100 - Drug Profile 96
QRX-411 - Drug Profile 97
QRX-421 - Drug Profile 98
ReN-003 - Drug Profile 99
RST-001 - Drug Profile 103
SAR-421869 - Drug Profile 105
SB-623 - Drug Profile 107
Small Molecule for Retinitis Pigmentosa - Drug Profile 112
Small Molecules 1 for Retinitis Pigmentosa - Drug Profile 113
Small Molecules 2 for Retinitis Pigmentosa - Drug Profile 114
Small Molecules 3 for Retinitis Pigmentosa - Drug Profile 115
Small Molecules 4 for Retinitis Pigmentosa - Drug Profile 116
Small Molecules for Retinitis Pigmentosa - Drug Profile 117
Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile 118
Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile 119
STC-1 - Drug Profile 120
Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 121
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 123
Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile 125
Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile 126
Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile 128
voretigene neparvovec - Drug Profile 129
zuretinol acetate - Drug Profile 135
Retinitis Pigmentosa (Retinitis) - Dormant Projects 141
Retinitis Pigmentosa (Retinitis) - Discontinued Products 143
Retinitis Pigmentosa (Retinitis) - Product Development Milestones 144
Featured News & Press Releases 144
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by 2-BBB Medicines BV, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Eyevensys SAS, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Ms Science Corp, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by MimeTech Srl, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Recursion Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2017
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Retinitis Pigmentosa (Retinitis) - Overview 8
Retinitis Pigmentosa (Retinitis) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 28
2-BBB Medicines BV 28
Acucela Inc 28
Allergan Plc 28
Amarantus Bioscience Holdings Inc 29
Amgen Inc 29
Applied Genetic Technologies Corp 30
Astellas Pharma Inc 30
Caladrius Biosciences Inc 31
Dompe Farmaceutici SpA 31
Eyevensys SAS 32
GenSight Biologics SA 32
Grupo Ferrer Internacional SA 33
ID Pharma Co Ltd 33
InFlectis BioScience 33
Ionis Pharmaceuticals Inc 34
Ms Science Corp 34
MimeTech Srl 35
Mimetogen Pharmaceuticals Inc 35
Nanovector srl 35
Novartis AG 36
Novelion Therapeutics Inc 36
ProQR Therapeutics NV 37
Recursion Pharmaceuticals Inc 37
ReNeuron Group Plc 38
SanBio Inc 38
Sanofi 39
Spark Therapeutics Inc 39
Sun Pharma Advanced Research Company Ltd 40
Retinitis Pigmentosa (Retinitis) - Drug Profiles 41
A-004 - Drug Profile 41
AGTC-501 - Drug Profile 43
AMRS-001 - Drug Profile 45
Antibodies to Antagonize IL-6 for Retinitis - Drug Profile 54
Antisense Oligonucleotides to Activate Usherin for Retinitis Pigmentosa - Drug Profile 55
AP-1 - Drug Profile 56
cenegermin - Drug Profile 57
CPK-850 - Drug Profile 60
cutamesine - Drug Profile 61
EYS-611 - Drug Profile 63
FAB-111 - Drug Profile 64
Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 65
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 66
Gene Therapy for Ocular Diseases - Drug Profile 67
Gene Therapy for Retinitis Pigmentosa - Drug Profile 68
Gene Therapy for Retinitis Pigmentosa - Drug Profile 69
Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile 70
Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile 71
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile 72
Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile 73
Gene Therapy to Activate RdCVF for Retinitis Pigmentosa - Drug Profile 74
Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 75
Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 76
GS-030 - Drug Profile 77
HORAPDE-6B - Drug Profile 80
HORARLBP-1 - Drug Profile 81
HORARPE-65 - Drug Profile 82
IFB-088 - Drug Profile 83
IONISRHO-2.5Rx - Drug Profile 84
KIRA-6 - Drug Profile 85
KUS-121 - Drug Profile 86
KUS-187 - Drug Profile 87
LPDF-003 - Drug Profile 88
MT-8 - Drug Profile 89
myriocin - Drug Profile 90
N-acetyl cysteine amide - Drug Profile 91
NPI-001 - Drug Profile 92
NT-501 - Drug Profile 93
OCU-100 - Drug Profile 96
QRX-411 - Drug Profile 97
QRX-421 - Drug Profile 98
ReN-003 - Drug Profile 99
RST-001 - Drug Profile 103
SAR-421869 - Drug Profile 105
SB-623 - Drug Profile 107
Small Molecule for Retinitis Pigmentosa - Drug Profile 112
Small Molecules 1 for Retinitis Pigmentosa - Drug Profile 113
Small Molecules 2 for Retinitis Pigmentosa - Drug Profile 114
Small Molecules 3 for Retinitis Pigmentosa - Drug Profile 115
Small Molecules 4 for Retinitis Pigmentosa - Drug Profile 116
Small Molecules for Retinitis Pigmentosa - Drug Profile 117
Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile 118
Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile 119
STC-1 - Drug Profile 120
Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 121
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 123
Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile 125
Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile 126
Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile 128
voretigene neparvovec - Drug Profile 129
zuretinol acetate - Drug Profile 135
Retinitis Pigmentosa (Retinitis) - Dormant Projects 141
Retinitis Pigmentosa (Retinitis) - Discontinued Products 143
Retinitis Pigmentosa (Retinitis) - Product Development Milestones 144
Featured News & Press Releases 144
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160
List Of Tables
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by 2-BBB Medicines BV, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Eyevensys SAS, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Ms Science Corp, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by MimeTech Srl, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Recursion Pharmaceuticals Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H2 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2017
List Of Figures
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
RELATED REPORTS
Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H2, 2021
Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H2, 2021 provides an overview of Retinitis Pigmentosa (Retinitis)
View ReportRetinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H1, 2021
Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H1, 2021GlobalDatas clinical trial report, Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H1, 2021 provides an overview of Retinitis Pigmentosa (Retinitis)
View ReportRetinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H2, 2021
Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H2, 2021 provides an overview of Retinitis Pigmentosa (Retinitis)
View ReportRetinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H1, 2021
Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H1, 2021GlobalDatas clinical trial report, Retinitis Pigmentosa (Retinitis) - Global Clinical Trials Review, H1, 2021 provides an overview of Retinitis Pigmentosa (Retinitis)
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
